I

Instil Bio Inc
NASDAQ:TIL

Watchlist Manager
Instil Bio Inc
NASDAQ:TIL
Watchlist
Price: 28.44 USD 2.97%
Market Cap: 186.6m USD

EV/EBIT
Enterprise Value to EBIT

-3.3
Current
-6.3
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.3
=
Enterprise Value
167.1m USD
/
EBIT
-50.8m USD
Market Cap EV/EBIT
US
Instil Bio Inc
NASDAQ:TIL
186.5m USD -3.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 883.8
US
Abbvie Inc
NYSE:ABBV
336.6B USD 22.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
165.5B USD 24.5
US
Gilead Sciences Inc
NASDAQ:GILD
140.7B USD 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
122.9B USD 27.8
US
Epizyme Inc
F:EPE
94.1B EUR -563.6
AU
CSL Ltd
ASX:CSL
128.6B AUD 23.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.3B USD 13.9
US
Seagen Inc
F:SGT
39.3B EUR -59.9
EBIT Growth EV/EBIT to Growth
US
I
Instil Bio Inc
NASDAQ:TIL
Average EV/EBIT: 21.1
Negative Multiple: -3.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 883.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.5
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.6 N/A N/A
AU
CSL Ltd
ASX:CSL
23.5
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-2
2-Years Forward
EV/EBIT
-2
3-Years Forward
EV/EBIT
-1.7